NCT00499837View on ClinicalTrials.gov

Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Cystic Fibrosis
Interventions
DRUG

Aerosolized, human, plasma-derived Alpha-1 Antitrypsin

Trial Locations (1)

91240

Hadassah Hebrew University, Medical Center, Jerusalem

All Listed Sponsors
lead

Kamada, Ltd.

INDUSTRY

NCT00499837 - Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients | Biotech Hunter | Biotech Hunter